In May 2023 Croda International Plc (UK) entered into a partnership with Amyris (US) and Botanical Solutions Inc. (BSI) firstly for biotechnology-derived squalene and secondly with BSI for develop a sustainable QS-21 vaccine adjuvant moving towards plant tissue culture-derived approach rather than traditional method of extracting QS-21 from soap bark trees.

Northbrook, IL 60062 -- (SBWire) -- 10/04/2023 --The vaccine adjuvants industry is poised for remarkable growth in the near future, as the global demand for effective vaccines continues to surge. With ongoing advancements in vaccine technology and an increasing emphasis on vaccine development for emerging infectious diseases, the adjuvant market is set to play a pivotal role in enhancing vaccine efficacy and reducing production costs. Innovations in adjuvant formulations, such as the development of more potent and targeted adjuvants, will likely contribute to the creation of safer and more effective vaccines. Additionally, as governments and organizations worldwide prioritize pandemic preparedness, the vaccine adjuvants sector is expected to witness significant investments, fostering research and development, and driving substantial market expansion. This dynamic landscape holds the promise of revolutionizing vaccine development, ultimately leading to improved public health outcomes on a global scale.

Vaccine Adjuvants Market in terms of revenue was estimated to be worth $0.8 billion in 2023 and is poised to reach $1.2 billion by 2028, growing at a CAGR of 6.9 % from 2023 to 2028 according to a new report by MarketsandMarkets™. The global vaccine adjuvants market is expected to grow at a CAGR of 6.9% during the forecast period. The major factors driving the growth of the market are collaborations & partnerships among market players for vaccine adjuvants development, increasing focus on immunization programs and rise in number of vaccine approvals in last 2-3 years.

Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=152603894

Browse in-depth TOC on "Vaccine Adjuvants Market"
200 - Tables
45 - Figures
230 - Pages

The adjuvant emulsions segment is expected to have the dominant share of the vaccine adjuvants market in 2022:

Based on product, the global vaccine adjuvants market is segmented into adjuvant emulsions, pathogen components, saponin-based adjuvants, particulate adjuvants, and other adjuvants. In 2022, the adjuvant emulsions segment accounted for largest share of the vaccine adjuvants market. Increased use of adjuvant emulsions in the vaccine production is serving as driving factor for the growth of the adjuvant emulsions segment during the forecast period.

The infectious disease segment accounted for the largest share of the disease type segment in the vaccine adjuvants market in 2022.

The infectious diseases segment is the fastest growing segment and accounted for the largest share of the market in 2022. The large share of this segment can be attributed to rising demand for novel adjuvanted vaccines for infectious diseases. Rising focus on development of plant-based adjuvants is further likely to have positive impact on the segmental growth.

The Asia Pacific region is the fastest-growing region of the vaccine adjuvants market in 2022.

The Asia Pacific is estimated to be the fastest-growing segment of the market. The growth of the vaccine adjuvants markets on the region is driven by rising emphasis on strategic initiatives such as partnerships, collaborations & expansion and increased adoption of adjuvanted vaccine among the patent population.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=152603894

Vaccine Adjuvants Market Dynamics:

Drivers:

Rising prevalence of infectious diseases

Restraints:

Side Effects and High Toxicity of Adjuvants

Opportunities:

Rising funding for vaccines and infectious disease research activities

Challenges:

Concerns regarding animal-sourced vaccine adjuvants and limitations on shark fishing

Key Market Players:

The vaccine adjuvants market is competitive, with a small number of players competing for market shares. Dynavax Technologies (US), GSK plc (UK), Croda International plc (UK), SEPPIC (France), Novavax (US), SPI Pharma (Associated British Foods plc) (UK), Agenus Inc. (US), Phibro Animal Health Corporation (US), Aurorium (Vertellus) (US), Merck KGaA (Germany) are some of the leading players in this market. Most companies in the market focus on organic and inorganic growth strategies, such as product launches, expansions, acquisitions, partnerships, agreements, and collaborations, to increase their product offerings, cater to the unmet needs of customers, increase their profitability, and expand their presence in the global market.

Get 10% Free Customization on this Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=152603894

Vaccine Adjuvants Market Advantages:

Enhanced Immunogenicity: Adjuvants help boost the immune response to vaccines, leading to a more robust and long-lasting immune memory. This is particularly important for vaccines targeting diseases that are challenging to prevent or require frequent booster shots.

Dose-Sparing Effect: Adjuvants allow for the reduction of the antigen content in vaccines, which can be crucial in situations where there is a shortage of vaccine ingredients or when rapid mass vaccination campaigns are required.

Improved Vaccine Efficacy in Vulnerable Populations: Adjuvants can be tailored to enhance immune responses in specific populations, such as the elderly or individuals with weakened immune systems, making vaccines more effective for those who need them most.

Expanded Vaccine Coverage: Adjuvants can extend the reach of vaccines to previously unresponsive pathogens, broadening the range of diseases that can be effectively prevented.

Cost-Effectiveness: By reducing the amount of antigen required per dose and potentially decreasing the need for booster shots, adjuvants can lower the overall cost of vaccine production and distribution.

Rapid Response to Emerging Infectious Diseases: Adjuvants can facilitate the rapid development of vaccines in response to newly emerging infectious diseases, helping to contain outbreaks more effectively.

Tailored Immunization Strategies: Adjuvants allow for the customization of vaccine formulations to target specific pathogens or address unique challenges associated with particular diseases, increasing the versatility of vaccine development.

Safer Vaccines: Adjuvants can contribute to the development of safer vaccines by improving their efficacy, potentially reducing the need for higher antigen concentrations, and enhancing the overall vaccine profile.
In summary, vaccine adjuvants offer a range of advantages that contribute to the development of more effective, efficient, and adaptable vaccines, ultimately benefiting public health by preventing and controlling a wide range of infectious diseases.

Recent Developments:

In May 2023 Croda International Plc (UK) entered into a partnership with Amyris (US) and Botanical Solutions Inc. (BSI) firstly for biotechnology-derived squalene and secondly with BSI for develop a sustainable QS-21 vaccine adjuvant moving towards plant tissue culture-derived approach rather than traditional method of extracting QS-21 from soap bark trees.
In August 2022, GSK Plc (UK) entered into acquisition with Affinivax, Inc. (US) in order to develop pneumococcal vaccines.
In October 2021, Dynavax Technologies (US) entered into a fully funded collaboration with the US Department of Defense to conduct a Phase 2 clinical trial for a plague vaccine adjuvanted with CpG 1018.

About MarketsandMarkets™:

MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.

The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.

Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.

To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter, LinkedIn and Facebook.

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com